[Treatment of NSAIDs induced ulcers].
Mizokami
Yuji
Y
Department of Internal Medicine 5, Kasumigarua Hospital, Tokyo Medical University.
Shiraishi
Takahisa
T
Otsubo
Toshiya
T
Nakamura
Hiroshi
H
Miyazawa
Kenshi
K
Narushima
Katsuhiko
K
Matsuoka
Takeshi
T
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D016595:Misoprostol / Q000627:therapeutic use*; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012189:Retrospective Studies; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D016595:Misoprostol; D064747:Lansoprazole; D015738:Famotidine; D009853:Omeprazole